Company profile: Blade Therapeutics
1.1 - Company Overview
Company description
- Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestatβa Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184βan IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
Products and services
- Autotaxin Inhibitor: Oral small-molecule class targeting autotaxin to treat fibrotic diseases, developed to inhibit the autotaxin enzyme
- Cudetaxestat: Phase 2-ready treatment for Idiopathic Pulmonary Fibrosis utilizing a non-competitive autotaxin inhibition mechanism, created to inhibit autotaxin through a non-competitive mode of action
- Calpain Inhibitor: Small-molecule therapies inhibiting dimeric calpains for potential treatment of fibrosis and neurodegenerative diseases, produced as targeted enzyme inhibitors
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Blade Therapeutics
BioSenic
HQ: United States
Website
- Description: Provider of therapies addressing innate immunity, inflammation, and organ/function repair, including arsenic trioxide-based treatments for autoimmune diseases and chronic graft versus host disease (ArsciCor, an oral formulation with rapid gastrointestinal solubilization and optimal bioavailability), cell therapy products for major bone defects and maxillofacial applications, and a Phase III trial of oral arsenic trioxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full BioSenic company profile β
Evommune
HQ: United States
Website
- Description: Provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCΞΈ inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Evommune company profile β
EpiBiologics
HQ: United States
Website
- Description: Provider of antibody-based targeted therapies and platforms for tissue-specific degradation of disease-driving membrane and extracellular proteins, including the EpiTAC platform (bispecific antibody system), AbTACs, KineTACs, TrainTAC degrader, and the EpiAtlas platform with a library of over 270 degrader arms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full EpiBiologics company profile β
Ception Therapeutics
HQ: United States
Website
- Description: Provider of payroll management services, delivering customizable payroll solutions and advanced software for seamless, timely processing; comprehensive administration covering tax filings and employee deductions; payroll compliance with the latest laws and regulations; and consulting on best practices and audit assistance, allowing businesses to focus on growth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Ception Therapeutics company profile β
BioXell
HQ: Italy
Website
- Description: Provider of recombinant protein expression and purification services; stable cell line generation using proprietary ExoIN technology and cGMP-compliant CHO-based platforms; transient protein expression; customized protein expression screening; high-yield recombinant protein production in E. coli, yeast, and mammalian systems; and monoclonal and polyclonal antibody development via hybridoma and phage display.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full BioXell company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Blade Therapeutics
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Blade Therapeutics
2.2 - Growth funds investing in similar companies to Blade Therapeutics
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Blade Therapeutics
4.2 - Public trading comparable groups for Blade Therapeutics
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β